Monday, July 23, 2012

Alzheimer's drug bapineuzumab fails late-stage trial

A closely watched Alzheimer's drug trial failed a late-stage test, Pfizer Inc. said Monday. The trial is the first of four with bapineuzumab by Pfizer partner Janssen Alzheimer Immunotherapy R&D LLC of South San Francisco. The trial of the intravenous drug focused on patients with mild-to-moderate Alzheimer's disease who carry a specific genotype called ApoE4.

No comments:

Post a Comment